These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 35681611)

  • 1. Sensitization of Resistant Breast Cancer Cells with a Jumonji Family Histone Demethylase Inhibitor.
    Singh B; Sarli VN; Lucci A
    Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitization of Resistant Cells with a BET Bromodomain Inhibitor in a Cell Culture Model of Deep Intrinsic Resistance in Breast Cancer.
    Singh B; Sarli VN; Milligan RD; Kinne HE; Shamsnia A; Washburn LJ; Addanki S; Lucci A
    Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A usable model of "decathlon winner" cancer cells in triple-negative breast cancer: survival of resistant cancer cells in quiescence.
    Singh B; Sarli VN; Washburn LJ; Raythatha MR; Lucci A
    Oncotarget; 2018 Feb; 9(13):11071-11082. PubMed ID: 29541397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of resistant triple-negative breast cancer cells with low-dose 6-mercaptopurine and 5-azacitidine.
    Singh B; Sarli VN; Lucci A
    Oncotarget; 2021 Mar; 12(7):626-637. PubMed ID: 33868584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells.
    Salem I; Alsalahi M; Chervoneva I; Aburto LD; Addya S; Ott GR; Ruggeri BA; Cristofanilli M; Fernandez SV
    Breast Cancer Res; 2016 Mar; 18(1):37. PubMed ID: 27009091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells.
    Banelli B; Daga A; Forlani A; Allemanni G; Marubbi D; Pistillo MP; Profumo A; Romani M
    Oncotarget; 2017 May; 8(21):34896-34910. PubMed ID: 28432280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Jumonji-domain histone demethylase inhibitor JIB-04 deregulates oncogenic programs and increases DNA damage in Ewing Sarcoma, resulting in impaired cell proliferation and survival, and reduced tumor growth.
    Parrish JK; McCann TS; Sechler M; Sobral LM; Ren W; Jones KL; Tan AC; Jedlicka P
    Oncotarget; 2018 Sep; 9(69):33110-33123. PubMed ID: 30237855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth.
    Wang L; Chang J; Varghese D; Dellinger M; Kumar S; Best AM; Ruiz J; Bruick R; Peña-Llopis S; Xu J; Babinski DJ; Frantz DE; Brekken RA; Quinn AM; Simeonov A; Easmon J; Martinez ED
    Nat Commun; 2013; 4():2035. PubMed ID: 23792809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of 6-mercaptopurine in a cell culture model of adaptable triple-negative breast cancer with metastatic potential.
    Singh B; Sarli VN; Kinne HE; Shamsnia A; Lucci A
    Oncotarget; 2019 Jun; 10(38):3681-3693. PubMed ID: 31217902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Important Role of FTO in the Survival of Rare Panresistant Triple-Negative Inflammatory Breast Cancer Cells Facing a Severe Metabolic Challenge.
    Singh B; Kinne HE; Milligan RD; Washburn LJ; Olsen M; Lucci A
    PLoS One; 2016; 11(7):e0159072. PubMed ID: 27390851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells.
    Hu K; Law JH; Fotovati A; Dunn SE
    Breast Cancer Res; 2012 Feb; 14(1):R22. PubMed ID: 22309939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting of apoptotic pathways by SMAC or BH3 mimetics distinctly sensitizes paclitaxel-resistant triple negative breast cancer cells.
    Panayotopoulou EG; Müller AK; Börries M; Busch H; Hu G; Lev S
    Oncotarget; 2017 Jul; 8(28):45088-45104. PubMed ID: 28187446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery.
    Shadbad MA; Safaei S; Brunetti O; Derakhshani A; Lotfinejad P; Mokhtarzadeh A; Hemmat N; Racanelli V; Solimando AG; Argentiero A; Silvestris N; Baradaran B
    Genes (Basel); 2021 Aug; 12(8):. PubMed ID: 34440380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
    Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
    Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel Resistance Modulated by the Interaction between TRPS1 and AF178030.2 in Triple-Negative Breast Cancer.
    Zhao T; Zhang T; Zhang Y; Zhou B; Lu X
    Evid Based Complement Alternat Med; 2022; 2022():6019975. PubMed ID: 35399640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selection of metastatic breast cancer cells based on adaptability of their metabolic state.
    Singh B; Tai K; Madan S; Raythatha MR; Cady AM; Braunlin M; Irving LR; Bajaj A; Lucci A
    PLoS One; 2012; 7(5):e36510. PubMed ID: 22570721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small-molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids.
    Oner E; Kotmakci M; Baird AM; Gray SG; Debelec Butuner B; Bozkurt E; Kantarci AG; Finn SP
    J Nanobiotechnology; 2021 Mar; 19(1):71. PubMed ID: 33685469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 silencing inhibits triple-negative breast cancer development and upregulates T-cell-induced pro-inflammatory cytokines.
    Lotfinejad P; Kazemi T; Safaei S; Amini M; Roshani Asl E; Baghbani E; Sandoghchian Shotorbani S; Jadidi Niaragh F; Derakhshani A; Abdoli Shadbad M; Silvestris N; Baradaran B
    Biomed Pharmacother; 2021 Jun; 138():111436. PubMed ID: 33667790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing poly (ADP-ribose) polymerase inhibition through combined epigenetic and immunotherapy.
    Prasanna T; Wu F; Khanna KK; Yip D; Malik L; Dahlstrom JE; Rao S
    Cancer Sci; 2018 Nov; 109(11):3383-3392. PubMed ID: 30230653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated HDAC activity and altered histone phospho-acetylation confer acquired radio-resistant phenotype to breast cancer cells.
    Sharda A; Rashid M; Shah SG; Sharma AK; Singh SR; Gera P; Chilkapati MK; Gupta S
    Clin Epigenetics; 2020 Jan; 12(1):4. PubMed ID: 31900196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.